Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Abstract : Simple Summary Myelodysplastic syndrome (MDS) is one of the most-common blood cancers in older individuals. Although azacitidine is the most-commonly used treatment for MDS, only 30–40% of patients respond to it, and responses may not be achieved up to six cycles of treatment. Moreover, there are no universally accepted prognostic models that will identify patients who are unlikely to benefit.
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
